Filing Details
- Accession Number:
- 0001209191-21-017527
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-03-03 20:34:47
- Reporting Period:
- 2021-03-01
- Accepted Time:
- 2021-03-03 20:34:47
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1754068 | Allovir Inc. | ALVR | Biological Products, (No Disgnostic Substances) (2836) | 831971007 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1763026 | M. Ann Leen | C/O Allovir, Inc. 139 Main Street, Suite 500 Cambridge MA 02142 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2021-03-01 | 6,359 | $38.46 | 2,465,326 | No | 4 | S | Indirect | See Footnote |
Common Stock | Disposition | 2021-03-01 | 3,159 | $39.18 | 2,462,167 | No | 4 | S | Indirect | See Footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | See Footnote |
No | 4 | S | Indirect | See Footnote |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 28,000 | Direct |
Footnotes
- This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.89 to $38.86. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.90 to $39.615. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.